0
Abstract: Poster Presentations |

A CLINICAL EXPERIENCE WITH BOSENTAN IN A HETEROGENEOUS PULMONARY HYPERTENSION POPULATION FREE TO VIEW

Abubakr A. Bajwa, MD*; Pablo Calvo, Medical Student; Javier Aduen, MD; Cesar Keller, MD; Charles D. Burger, MD
Author and Funding Information

Mayo Clinic, Jacksonville, FL



Chest. 2006;130(4_MeetingAbstracts):255S. doi:10.1378/chest.130.4_MeetingAbstracts.255S-a
Text Size: A A A
Published online

Abstract

PURPOSE: To describe the response to treatment and side-effects of pulmonary hypertension (PH) patients treated with bosentan.

METHODS: Retrospective analysis of consecutive PH patients in a single referral center.

RESULTS: Forty-seven PH patients were treated with bosentan. Five patients were excluded due to incomplete data. Of the remaining 42 patients, mean age was 59 ± 16 years. Thirty-one (74%) were women. The diagnostic categories were: primary pulmonary hypertension (PPH) 12 or 29%, connective tissue disease 10 or 24%, and PH out of proportion to co-existing lung disease 7 (17%). Most patients were WHO class 3 or 4 (22 or 52% and 15 or 36% respectively). Of the 37 (88%) patients with right heart catheterization prior to treatment, 27 had an acute vasodilator trial with epoprostenol and 18 were positive. Mean pulmonary artery systolic pressure (PASP) by echocardiogram prior to treatment was 80 ± 23. After at least 6-8 weeks of treatment, the PASP remained unchanged at 80 ± 24. Only 10 (24%) patients had clinical improvement. The clinical response rate was similar in PPH. Additional vasodilator therapy was initiated in 22 (52%) patients, including Flolan in 10 patients. Bosentan was discontinued in 21 of 42 patients (50%) usually due to side effects (11 patients). The most common side effect was liver enzyme elevation (9 patients). Overall mortality was high: 9 of 42 (21%). An additional 4 patients (9%) required lung transplant or heart lung transplant.

CONCLUSION: A minority of the patients responded to Bosentan therapy. The frequency of side effects noticed was higher than has been published.

CLINICAL IMPLICATIONS: The low clinical response rate and high drug intolerance may limit the utility of bosentan in patients with severe PH.

DISCLOSURE: Abubakr Bajwa, None.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543